AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Biomira Receives Patent Protection For Its Idiotypic Vaccines.(Brief Article)
2001 DEC 5 - (NewsRx.com & NewsRx.net) -- Biomira, Inc. (BIOM) announced that its subsidiary, Biomira USA, Inc., was issued a second patent from the U.S. Patent and Trademark Office for composition of matter used in Biomira's cancer vaccine program.
The issued patent, number 6,312,718, is entitled "Vaccine for B-cell Malignancies" and is pending worldwide.
The patent describes a new liposomal vaccine, which includes a purified or synthetic B-cell malignancy antigen and cytokines. A prototype vaccine was manufactured by Biomira and tested at the National Cancer Institute (NCI) by Dr. Larry Kwak in patients with non-Hodgkin lymphoma. The vaccine was prepared for each patient using individual B-cell lymphoma antigens. This Phase I clinical trial of individualized vaccine showed that it was well tolerated upon repeated administration and induced an immune response in the vaccinated patients. The clinical results are ...
- Biomira to Proceed Independently With Autologous Vaccine Program.
- Press release article from: PR Newswire March 30, 2001 700+ words
...This program is being conducted through Biomira Inc.'s wholly owned subsidiary, Biomira USA of Cranbury, NJ in collaboration with...Cancer Institute and other Cancer Centers in New Jersey. Biomira is a biotechnology company specializing...
- Biomira Receives Further U.S. Patent Protection For Its Idiotypic Vaccine...
- Press release article from: PR Newswire November 9, 2001 700+ words
...is being conducted through Biomira's wholly owned subsidiary, Biomira USA of Cranbury, NJ in collaboration...centres in Pennsylvania and New Jersey. "This patent, together...PhD, President and CEO, Biomira Inc. "This establishes an...
- Biomira Inc. Announces 4th Quarter and 1995 Results.
- Press release article from: Business Wire March 21, 1996 700+ words
...Radioimmunoimaging Partnership. Biomira expensed this acquisition consistent...and short term investments of Biomira at December 31, 1995 were...OncoTherapeutics, Inc., Cranbury, New Jersey. The harmony with Biomira's Cancer Management mission...
- Biomira Restructures Programs to Focus on Most Advanced Products; Company Seeks...
- Press release article from: PR Newswire November 28, 2001 700+ words
...PhD, President and CEO, Biomira Inc. "The Company is moving...R) vaccine. In addition, Biomira has been in discussions to...employees were laid off. The New Jersey subsidiary, where the programs...additional responsibilities for Biomira USA. Biomira is a biotechnology...
- Biomira Shareholders Approve Move to U.S.
- Press release article from: PR Newswire December 4, 2007 700+ words
...EDMONTON, Dec. 4 /PRNewswire-FirstCall/ -- Biomira Inc. (TSX: BRA) ("Biomira", the "Company") today announced that the...corporation of a successor corporation of the current Biomira and its subsidiaries. Upon the completion of...
- Biomira Announces Plan to Reincorporate in the United States.
- Press release article from: PR Newswire September 12, 2007 700+ words
...Sept. 12 /PRNewswire-FirstCall/ -- Biomira Inc. (TSX: BRA) (the "Company...subject to shareholder and court approval, Biomira will migrate to the United States by creating...corporation based in the State of Delaware, Biomira Corporation, which will be the ultimate...
- Biomira Revises Collaboration Agreement with Chiron: Biomira Options To...
- Press release article from: PR Newswire September 2, 1999 700+ words
Biomira Signs Common Stock Equity Line For Up To...EDMONTON, AB, Sept. 2 /CNW-PRN/ - Biomira Inc. (Nasdaq: BIOM) (TSE, ME: BRA...collaboration with Chiron Corporation. Biomira has signed an option agreement with Chiron...
- Biomira and Inno-Centre Alberta Create Spin-Off Company to Further Develop...
- Press release article from: PR Newswire May 20, 2004 700+ words
Biomira Inc. (TSX:BRA) and Inno- centre Alberta...to re- enter clinical trials in 2005. Biomira had previously suspended clinical development...IL-2 in order to focus attention on Biomira's two lead product candidates, Theratope...